Elevated systemic interleukin-7 in patients with colorectal cancer and individuals at high risk of cancer: association with lymph node involvement and tumor location in the right colon by unknown
1 3
Cancer Immunol Immunother (2017) 66:171–179
DOI 10.1007/s00262-016-1933-3
ORIGINAL ARTICLE
Elevated systemic interleukin‑7 in patients with colorectal cancer 
and individuals at high risk of cancer: association with lymph 
node involvement and tumor location in the right colon
Malgorzata Krzystek‑Korpacka1  · Marek Zawadzki2 · Katarzyna Neubauer3 · 
Iwona Bednarz‑Misa1 · Sabina Górska4 · Jerzy Wis´niewski1 · Wojciech Witkiewicz2,5 · 
Andrzej Gamian1,4 
Received: 24 April 2016 / Accepted: 14 November 2016 / Published online: 19 November 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
our study is the first to demonstrate IL-7 elevation in CRC 
in association with metastatic disease and tumor location. 
Both associations should be considered when designing IL-
7-based immunotherapies for CRC. Further studies on IL-7 
functionality in CRC are necessary.
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Abstract Interleukin (IL)-7 is a cytokine essential for pro-
tective immunity, and it is considered as a promising agent 
for cancer immunotherapy. Recent studies, however, appear 
to associate IL-7 with aggressiveness of solid tumors. The 
IL-7 has been less studied in colorectal cancer (CRC) and 
conditions associated with increased risk of CRC devel-
opment. To explore IL-7 status in bowel diseases, it was 
measured immunofluorometrically in 431 individuals (110 
with CRC) by using Luminex platform. A level of IL-7 in 
CRC patients was significantly higher than in controls, did 
not differ from those with adenomas, but was lower than in 
both active and inactive inflammatory bowel disease (IBD) 
cases. In CRC, IL-7 was higher in patients with lymph node 
and distant metastases and with tumors located in right 
colon. In adenomas, IL-7 elevation was associated exclu-
sively with villous growth pattern, while in IBD, circulating 
IL-7 reflected clinical activity of Crohn’s disease and ulcer-
ative colitis. Systemic TNFα, IL-10, and PDGF-BB were 
independent predictors of circulating IL-7. In summary, 
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UC  Ulcerative colitis
UICC TNM classification  Union Internationale Contre le 
Cancer tumor-node-metastasis 
system for classification of 
malignant tumors
VEGF  Vascular endothelial growth 
factor
Introduction
Colorectal cancer (CRC) remains one of the commonest 
and most lethal cancers worldwide [1, 2]. CRC develop-
ment is frequently preceded by formation of adenomas. 
Although benign, these lesions may develop into cancer 
through a sequence of genetic and epigenetic alterations. A 
prevalence of the adenomas in older population is relatively 
high [3, 4]. Inflammatory bowel disease (IBD) is another 
pathology closely associated with an increased risk of 
CRC development. Inflammatory character of the disease 
combined with its incurableness, chronicity, and relapsing-
remitting nature eventually causes dysplasia and facili-
tates neoplastic transformation [5]. While survival rates 
for CRC patients with the resectable tumors are improv-
ing, the prognosis for patients with advanced CRC remains 
poor, rendering development of new therapeutic strategies a 
necessity. Immunotherapy, an approach based on boosting 
immune system to fight cancer, is a promising strategy that 
may improve outcomes for the CRC patients with meta-
static disease or cancers resistant to chemo- and/or radio-
therapy. It has also potential to prevent disease relapse, fol-
lowing radical tumor resection or eradication, facilitated by 
residual circulating cells, micrometastases or cancer stem 
cells [6].
Interleukin (IL)-7 is a pleiotropic cytokine, crucial for 
development and homeostasis of lymphocytes T, acting as 
their mitogen, growth and survival factor. IL-7 is ubiqui-
tous and mainly tissue-derived cytokine [7–9]. Owing to 
its central role in innate and adaptive immunity, IL-7 has 
been listed as one of the “Top Agents with High Potential 
for Use in Treating Cancer” by the panel of experts at the 
National Cancer Institute Immunotherapy Agent Workshop 
in 2007 [10]. IL-7 may up-regulate tumor-directed immune 
responses in a number of ways, including, but not limited 
to, enhancement of the cellular (Th1) immune response 
or selective expansion of the tumor-redirected cytotoxic 
T lymphocytes [8, 9, 11, 12]. Unlike the other γ-chain 
cytokines tested as therapeutics (e.g. IL-2), application of 
IL-7 in cancer immunotherapy is particularly appealing, 
because it does not induce hyperinflammation [13, 14]. 
Since IL-7 plays a role in both predisposing to autoim-
munity and in perpetuating autoimmune inflammation [7], 
targeting IL-7/IL7R signaling appears to be an attractive 
therapeutic option for preventing CRC [15].
However, there is an increasing number of reports show-
ing IL-7 to be overexpressed by solid tumors [11, 16–19] 
and being elevated in sera of the cancer patients [20–24]. 
Although functional data are still scanty, available evidence 
seems to link IL-7 overexpression with tumor aggressive-
ness, metastasis, and unfavorable prognosis [11, 19].
In the light of growing interest in immunotherapy based 
on this cytokine and controversies associated with its 
expression by solid tumors, we aimed at exploring IL-7 
status in CRC and conditions linked to an increased risk 




Systemic IL-7 was measured in serum samples from 431 
individuals: 110 with CRC, 21 with adenomas, 171 with 
IBD (133 with active and 38 with inactive disease; 97 with 
Crohn’s disease (CD) and 74 with ulcerative colitis (UC)), 
and 129 controls. Enrolled CRC patients were admitted to 
the Department of Surgical Oncology, Regional Special-
ist Hospital in Wroclaw in years 2013–2015 for curative 
resection of histologically confirmed adenocarcinoma of 
colon or rectum. Patients aged <18 years, with poor overall 
physical status (ASA physical status classification system 
>3), requiring emergency surgery, with gross metastatic 
disease or locally advanced cancers not amenable to cura-
tive resection were excluded. Resected tumors were staged 
pathomorphologically according to UICC TNM 7th edi-
tion from 2010 and stage distribution is given in Table 1. 
Individuals with IBD and adenomas were inpatients of the 
Department of Gastroenterology and Hepatology of Wro-
claw Medical University. Patients with indeterminate coli-
tis or the co-existence of other severe systemic diseases, 
malignancies, liver diseases, or pregnancies were excluded. 
Crohn’s Disease Activity Index (CDAI) was applied for the 
assessment of CD activity and the Mayo Scoring System 
(MDAI) for UC. IBD patients, with few exceptions, were 
treated with 5′-aminosalicylate derivatives. Twelve patients 
with adenomas had multiple polyps, in nine the polyps 
were larger than 10 mm, and in eight the polyps had villous 
growth pattern. Control group consisted of healthy volun-
teers from hospital staff, outpatients of Research, Science, 
and Educational Center of Dementia Diseases, Scinawa, 
Poland, suffering from headaches or mild cognitive disor-
ders (Alzheimer disease and other forms of dementia were 
excluded using neuroimaging and the following criteria: 
173Cancer Immunol Immunother (2017) 66:171–179 
1 3
ICD-10, DSM IV, and NINCDS-ADRDA as revised in 
2007), patients with non-malignant and non-inflammatory 
bowel diseases (irritable bowel syndrome, diverticulosis, 
hemorrhoids) and blood donors, whose sera were kindly 
provided by Regional Center of Blood Donation and Thera-
peutics in Wroclaw, Poland. Inclusion criteria for control 
group were: age >18 years, overall good health condition, 
and willingness to participate. Exclusion criteria were preg-
nancy, active inflammation, known severe systemic disease, 
dementia or depression.
Subjects distribution based on gender (females/males) 
in CRC, adenoma, active IBD, inactive IBD and con-
trol cohorts did not differ significantly (p = 0.673) and 
was as follows: 43/67, 11/10, 63/70; 16/22, and 57/72. 
Age distribution in CRC, adenoma, active IBD, inac-
tive IBD, and in control cohorts was as follows: 65 years 
(95% CI 64–68), 61.5 years (56–77), 33 years (31–36), 40 
years (29–44), and 50 years (42–56). Due to natural his-
tory of the diseases, median age in both IBD cohorts dif-
fered significantly from other groups (p < 0.05). However, 
IL-7 did not correlate with age in any evaluated cohort: 
p = 0.174 for CRC, p = 0.959 for adenomas, p = 0.156 
for active IBD, p = 0.681 for inactive IBD, and p = 0.196 
for controls. Nevertheless, control group was divided into 
subgroups based on age: <45 years (median age 34 years 
(33–38), n = 62) to match age distribution in IBD patients 
(p = 0.579) and ≥45 years (median age 64 years (62–65), 
n = 67) to match age distribution in CRC and adenoma 
patients (p = 0.295).
The study protocol was approved by the Medical Eth-
ics Committees of Wroclaw Medical University and of 
Regional Specialist Hospital, and the study was conducted 
in accordance with the Helsinki Declaration of 1975, as 
revised in 1983, and an informed consent has been obtained 
from all patients.
Analytical methods
Blood was drawn in a fasting state prior to any procedure 
by venipuncture, clotted for 30 min, and subsequently cen-
trifuged (15 min, 720×g). Collected serum was aliquoted 
and kept frozen at −80° until examination. Samples were 
measured in duplicates or triplicates by means of flow 
cytometry-based method utilizing magnetic microspheres 
conjugated with monoclonal antibodies using the Bio-
Plex 200 platform with HRF (Bio-Rad, USA), incorporat-
ing Luminex xMAP® technology. Bio-Plex Pro™ Human 
Cytokine, Chemokine, and Growth Factor Magnetic Bead-
Based Assays were used according to manufacturer’s 
instructions to measure the levels of IL-7 and IL-1β, IL-6, 
IL-8, IL-10, IL-12(p70), IFNγ, MCP-1, MIP-1α, MIP-1β, 
IP-10, FGF2, PDGF-BB, TNFα, and VEGF-A. Standard 
curves were drawn using 5-PL logistic regression, and the 
data were analyzed using BioPlex Manager 6.0 software.
Statistical analysis
Chi-squared test was applied to assess the normality of 
data distribution. Homogeneity of variation was evaluated 
using Levene test. Data were log-transformed to obtain 
normality. Normally distributed data are presented as geo-
metric means and analyzed using t test for independent 
samples with Welch correction if appropriate or one-way 
ANOVA with Bonferroni correction for multiple testing 
and Student–Newman–Keuls post hoc test. Non-normally 
distributed data are presented as medians and analyzed 
using Kruskal–Wallis H test. Both geometric means and 
medians are accompanied by 95% CI. Two-way ANOVA 
was employed to co-exam the effects of tumor location 
and regional metastases on IL-7. Correlation analysis was 
conducted using Spearman rank test (ρ) or Pearson test (r), 
depending on data character and distribution. Frequency 
analysis was conducted using Chi-square test. Enter and 
stepwise method of multivariate analysis was used to dis-
cern independent predictors of IL-7 and to determine 
partial correlation coefficients (net correlation with the 
effects of other variables removed). To limit the number 
of variables, we used two-step procedure. It allowed us to 
Table 1  Circulating IL-7 and CRC advancement
N Mean IL-7 (95% CI) P
Disease stage (UICC TNM7th) 0.027
0 5 5.95 (4–8.9)
I 8 8.32 (5.9–11.9)
II 41 10.59 (8.2–13.7)
III 47 12.74 (10.7–15.1)
IV 9 19.63 (7.2–80.7)
Primary tumor (T) 0.162
Tis 5 5.95 (4–8.9) 
T1 1 7.45
T2 11 10.73 (7.2–16)
T3 62 11.19 (9.2–13.6)
T4 31 14.22 (10.6–19.1)
Lymph node involvement (N) 0.018
No (N0) 54 9.69 (7.9–11.9)
Yes (N1/N2) 56 (33/23) 13.66 (11.2–16.7)
Distant metastases (M) 0.030
M0 101 11.01 (9.6–12.6)
M1 9 19.63 (72–53.6)
Grade of differentiation (G) 0.693
G1 9 9.35 (4.4–19.8)
G2 79 12.11 (10.1–14.5)
G3 15 12.94 (10.5–16)
G4 1 7.45
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eliminate insignificant variables in a first step so the ratio of 
variables-to-cases in a final model was acceptable (1:16). 
The following criteria were used: p < 0.05 for entering and 
p > 0.1 for removing of variables. Coefficient of determi-
nation adjusted for the number of independent variables in 
the regression model (R2-adjusted) represents the goodness 
of fit of the model. All calculated probabilities were two-
tailed, and p values ≤0.05 were considered statistically sig-
nificant. The statistical analysis was conducted using Med-
Calc Statistical Software version 16.2.0 (MedCalc Software 
bvba, Ostend, Belgium; https://www.medcalc.org; 2016).
Results
Circulating IL‑7 in bowel diseases
The concentration of IL-7 determined in sera from CRC 
patients was significantly higher than in controls, did not 
differ from patients with adenomas, and was significantly 
lower than in IBD, in both active and inactive cases of this 
disease (Fig. 1a).
Patients with adenomas had higher IL-7 than controls 
and lower than patients with active IBD, whose cytokine 
levels were significantly more elevated than in any other 
group except for inactive disease.
Owing to natural history of IBD and CRC with the dis-
eases onset, respectively, early and late in life, the con-
trol group could not be age-matched to both CRC and IBD 
cohorts. Although systemic IL-7 did not correlate with age, 
we re-analyzed the data after dividing our controls into two 
subgroups: one including younger individuals (age <45 years) 
to be compared with IBD patients and the other consisting of 
older individuals (age ≥45 years) to be compared with ade-
noma and CRC patients. It allowed us to confirm significance 
of the elevation of IL-7 in CRC, adenoma, and IBD patients 
as compared to controls in age-matched analysis (Fig. 1b, c).
Circulating IL‑7 and CRC advancement
A relation between CRC advancement and serum con-
centration of IL-7 is summarized in Table 1. Cytokine 
levels increased along with the disease stage (ρ = 0.29, 
p = 0.002) with a significant difference between stages 
0 and IV. Significant elevation in IL-7 concentration was 
associated also with lymph node involvement and pres-
ence of distant metastases. There was a weak positive 
Fig. 1  Systemic IL-7 in colorectal cancer and cancer high-risk con-
ditions. a Analysis on whole study population; b Analysis limited 
to IBD patients and their age-matched controls; c Analysis lim-
ited to CRC and adenoma patients and their age-matched controls. 
ADN, adenomas; CONT, controls; CRC, colorectal cancer; IBDa, 
active inflammatory bowel disease; IBDn, inactive inflammatory 
bowel disease. Data presented as medians with 95% CI and analyzed 
using Kruskal–Wallis H test. Lower script letters indicate signifi-
cant between-group differences. Outlying observations are presented 
together as open circles above dashed line and accompanied by IL-7 
values
▸
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correlation between IL-7 and T stage (ρ = 0.22, p = 0.021) 
and between IL-7 and a number of metastatic lymph nodes 
(ρ = 0.28, p = 0.013, n = 77).
Circulating IL‑7 and tumor location
Circulating IL-7 also differed with respect to tumor loca-
tion. Its concentration was significantly higher in serum of 
the patients with tumors localized in right colon (Fig. 2).
There was no difference in stage distribution 
(p = 0.493), lymph node involvement (p = 0.811), or 
presence of distant metastases (p = 0.265) between right-
sided CRC and other cancer locations. Moreover, when co-
examined in two-way ANOVA, both lymph node involve-
ment (F = 5.29, p = 0.023) and tumor location (F = 6.35, 
p = 0.013) were significantly and independently from each 
other associated with IL-7.
Circulating IL‑7 and CRC high‑risk conditions
There were no differences in systemic IL-7 between CD 
and UC, regardless whether patients with active or non-
active disease were compared. Cytokine levels positively 
correlated with the indices of clinical activity of both 
Crohn’s disease—CDAI (ρ = 0.3, p = 0.007) and ulcera-
tive colitis—Mayo score (ρ = 0.3, p = 0.008).
In adenoma group, there was no difference in IL-7 with 
respect to number of polyps (one vs. multiple, p = 0.983) 
or their size (10 < vs. ≥ 10 mm, p = 0.993). However, 
IL-7 was significantly higher in patients with adenomas 
displaying a villous growth pattern (villous adenomas and 
tubulovillous adenomas) as compared to tubular adenomas: 
20.6 pg/ml (95% CI 12.9–32.7) and 9.2 pg/ml (7.2–11.8), 
p = 0.001. Cytokine levels in patients with tubular adeno-
mas did not differ significantly from controls (p = 0.182).
Correlation pattern of IL‑7 with other cytokines
We evaluated the association between IL-7 and other 
cytokines and growth factors selected from among pro-/
anti-inflammatory and Th1/Th2 cytokines (IL-1β, IL-6, 
TNFα, IFNγ, IL12p(70), and IL-10), chemokines (MCP-1, 
MIP-1α, MIP-1β, and IL-8), and pro- and anti-angiogenic 
factors (IP10, FGF2, PDGF-BB, and VEGF-A). Circulating 
IL-7 was correlated with most of the evaluated cytokines 
and growth factors, except for MIP-1β and IP10. Particu-
larly strong correlations were observed for TNFα and IFNγ 
(Table 2).
Statistically, the examined cytokines were intertwined 
and to discern their independent associations and determine 
partial correlation coefficients, we applied two-step multi-
ple regression. First, we entered all cytokines significantly 
correlated with IL-7 in univariate analysis as independent 
variables. Then, cytokines with p > 0.1 were removed and 
remaining cytokines re-entered to analysis and stepwise 
method of model building was used. TNFα, IL-10, IL-1β, 
MCP-1, and PDGF-BB were entered in final model and 
TNFα, IL-10, and PDGF-BB remained as independent pre-
dictors of IL-7 explaining 64% of its variability (Table 3).
Discussion
In the context of cancer disease, interleukin (IL)-7 is 
viewed as a key therapeutic factor, while substantially 
less attention has been devoted to its possible association 
with the disease development. Occupying central posi-
tion in innate and adaptive immunity, IL-7 with its reper-
toire of antibacterial, anti-fungal, anti-viral, and anti-tumor 
activities is considered as “a critical enhancer of protec-
tive immunity” [25]. At the same time, mitogenic activity 
of IL-7 toward lymphoid populations might result in lym-
phoproliferative diseases. Accordingly, the cytokine has 
been implicated in the development and progression of 
leukemias and lymphomas [11, 17]. IL-7 association with 
solid tumors is relatively new and unexplored aspect of the 
research. Nevertheless, there is a growing body of evidence 
linking IL-7/IL-7R signaling with tumor aggressiveness, 
metastatic disease, and unfavorable prognosis [11, 17, 19, 
26]. There is paucity of data concerning IL-7 in CRC and 
conditions predisposing to the disease. IL-7 expression was 
found in tumor biopsies obtained from CRC patients [16], 
and it was reported by Crucitti et al. [21] to be significantly 
elevated in sera, while others linked IL-7 elevation to meta-
static disease [20] and poorer survival [24]. Our findings 
Fig. 2  Circulating IL-7 and tumor location. Data presented as geo-
metric means with 95% CI and analyzed using one-way ANOVA with 
Bonferroni corrections for multiple testing. Asterisk significantly dif-
ferent form other groups
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confirm systemic elevation of IL-7 in CRC and expand the 
knowledge by placing it in the broad context of health and 
non-malignant bowel diseases associated with increased 
risk of CRC development.
Contrary to data presented by Henry et al. [27] but 
corroborating findings of Comstock et al. [28], we have 
observed that circulating IL-7 was elevated in patients with 
adenomas, as compared to controls. Similar increase in sev-
eral other cytokines was reported elsewhere [28–31]. To 
resolve discrepancy between the reports, we investigated 
IL-7 in the context of adenomas, their number, size, and 
growth pattern. Detailed analysis revealed that IL-7 eleva-
tion coincided exclusively with villous growth pattern, while 
systemic IL-7 in patients with tubular adenomas was similar 
to controls. The dominant villous growth pattern is associ-
ated with large adenomas considered “advanced,” and they 
are more likely to progress into carcinoma [5]. The signifi-
cance of IL-7 elevation in advanced adenomas needs further 
clarification, but it might be of interest to mention that in 
benign prostatic hyperplasia IL-7 has been shown to stimu-
late proliferation of the prostatic cells (reviewed in [17]).
Chronic inflammation-induced dysplasia is another risk 
factor for neoplastic transformation, and the odds of CRC 
development are six-times higher in IBD patients than in 
general population. Moreover, IBD patients are more likely 
to have multiple synchronous CRC and their mortality is 
higher than in a case of sporadic cancers [32]. Corroborat-
ing reports published by others [33–35], we found IL-7 to 
be elevated in IBD as compared to controls. IL-7 elevation 
was more pronounced than in CRC, regardless whether 
the disease was active or IBD patients were in remission. 
Still, IL-7 weakly corresponded with clinical activity of 
both Crohn’s disease and ulcerative colitis. IL-7 elevation 
observed in IBD patients is consistent with findings by oth-
ers who reported higher percentage of activated and cycling 
CD4+ and CD8+ T cells and T cells expressing IFNγ as 
well as their increased resistance to apoptosis as compared 
to healthy individuals [15, 36]. The up-regulation of IL-7 
signaling in IBD had a worse treatment-refractory disease 
course, probably due to enriched pool of antigen-specific 
memory T cells which, upon future re-encounter with anti-
gen, would facilitate faster and more potent response from 
CD8 effector cells [37]. Intuitively, elevated IL-7 in IBD 
might confer at least some degree of protection against 
CRC development by promoting T cell mediated anti-
tumor responses. However, T cell responsiveness to IL-7 
has recently been demonstrated to be impeded by their 
exposure to inflammatory cytokines [38].
IL-7 is produced by stromal and epithelial cells as well 
as endothelial and immune cells. Its serum level is mainly 
regulated through the up-take by lymphocytes, thus elevat-
ing IL-7 in conditions associated with lymphopenia. The 
relevance of cytokine serum elevation found in cancer or 
the role of IL-7 expression and secretion by tumor cells 
remains elusive. Nonetheless, accumulated data seem to 
point at this cytokine involvement in metastasis [9, 11, 19]. 
Accordingly, our analysis of IL-7 association with clinico-
pathological features of CRC revealed that cytokine levels 
were more elevated in patients with lymph node involve-
ment. Moreover, IL-7 levels were dependent on PDGF-
BB and correlated with FGF2, VEGF-A, and IL-8, other 
potent angiogenic growth factors. Similar to Berghella’s 
et al. [20], we observed an increase in IL-7 in CRC patients 
with distant metastases despite a limited number of stage 
IV CRCs in current cohort. Our observations are consist-
ent with lymphangiogenic role attributed to IL-7 [17, 39]. 
In lung cancer, IL-7 protein expression has correlated with 
increased lymphovascular density, lymph node metastases, 
advanced clinical stage, VEGF-D, and cyclin D expression 
[39] and has been identified as a potent marker for bone 
metastasis [19]. In fact, bone invasion has been required 
to trigger an intense cytokine production and its increase 
in sera [19]. Similar association with nodal involvement, 
tumor aggressiveness and worse prognosis was observed 
for IL-7 and expression of its receptor by Al-Rawi et al. 
[40] in breast cancer. Moreover, overexpression of IL-7R in 
Table 2  IL-7 correlation pattern with inflammatory, Th1/Th2, chem-
otactic, and angiogenic cytokines
Cytokine Correlation coefficient, p
Inflammatory, Th1/Th2 IL-1β 0.52, p < 0.0001
TNFα 0.65, p < 0.0001
IL-6 0.40, p < 0.0001
IL-12(p70) 0.42, p < 0.0001
IFNγ 0.69, p < 0.0001
IL-10 0.57, p < 0.0001
Chemotactic MCP1 0.26, p = 0.007
MIP1α 0.34, p < 0.001
IL-8 0.21, p = 0.030
MIP1β 0.17, p = 0.072
Angiogenic FGF2 0.53, p < 0.0001
PDGF-BB 0.54, p < 0.0001
VEGF-A 0.20, p = 0.041
IP10 0.13, p = 0.176
Table 3  Multiple regression analysis with IL-7 as dependent variable
Partial correlation coefficient statistics t p
IL-10 0.494 5.78 <0.0001
PDGF-BB 0.411 4.63 0.002
TNFα 0.582 7.36 <0.0001
R
2 adjusted 0.642
F ratio, p 66.1, p < 0.0001
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lung adenocarcinomas was associated with tumor budding, 
which in turn has been associated with unfavorable out-
come. The tumor-immune interactions at the invading edge 
of tumors have been advocated as a driving force for their 
aggressiveness [41]. Functionally, IL7 has been shown to 
induce expression of VEGF-D and cyclin D in A549 cells 
and promote proliferation and lymphangiogenesis of lung 
cancer xenograft tumors [39]. Moreover, exogenous IL-7 
has been demonstrated to reduce the percentage of apop-
totic non-small cell lung cancer cells by up-regulating the 
expression of anti-apoptotic Bcl-2 and down-regulating the 
expression of pro-apoptotic Bax and p53 [42].
An interesting observation reported in this study is a 
significant variation in systemic IL-7 levels with respect to 
tumor location. Although collectively referred to as colo-
rectal cancer, the disease is heterogeneous and argued to 
encompass three entities, i.e., cancers of the right or left 
colon and rectal cancer [43, 44]. In general, the right colon 
cancers are considered to be more aggressive, poorly dif-
ferentiated, and associated with worse prognosis than the 
left colon cancers [45]. To address the differences between 
these two colon cancers Glebov at el. [44] identified over 
1300 genes that were differently expressed by right and 
left colon. However, the issue of possible differences being 
reflected on systemic level has not been explored. We 
observed IL-7 to be significantly more elevated in right 
than left or rectal cancers, and the association was not 
mediated by differences in stage or metastatic lymph node 
distribution. Taking into account advocated link between 
IL-7 signaling and tumor aggressiveness and hence worse 
prognosis [11, 17], more pronounced IL-7 elevation in right 
colon cancers might contribute to unfavorable outcomes 
associated with that tumor location. Interestingly, a total 
lymphocyte count was significantly lower in patients with 
right compare to left colon location of the tumors (data not 
shown). If systemic IL-7 reflects its intestinal expression, 
one of possible explanations of differences in IL-7 with 
respect to tumor location might be related to differences 
in bacterial load and composition in these two locations. 
Yoshioka et al. [46] reported that bacterial products such as 
flagellin might suppress IL-7 production by intestinal epi-
thelial cells.
The rationale behind IL-7-based therapies is its capability 
to selectively expand subpopulations of T lymphocytes. IL-7 
preferentially increases number of recent thymic emigrants, 
naïve, and central memory T cells [7] as well as tumor-redi-
rected cytotoxic T lymphocytes [12]. In turn, expansion of 
the regulatory T cells is negligible, rendering their percent-
age in total lymphocyte population relatively decreased [7]. 
Similarly, by up-regulating the count of other subsets, IL-7 
relatively reduces percentage of the senescent T cells [7]. 
Moreover, IL-7 protects T cells against tumor-induced senes-
cence and thus abrogates their proangiogenic activity [47]. 
A number of researchers have recently reported success-
ful application of IL-7. Wu et al. [48] used IL-7 to expand 
ex vivo Vδ1 T cells isolated from peripheral blood, which 
then was successfully used to restrain the tumor growth and 
improved survival of mice with xenografted human colon car-
cinoma. Zhao et al. [49] reported IL-7 insertion to autologous 
tumor vaccine modified with a virus that enhanced cytotoxic-
ity and production of IFNγ of tumor-infiltrating CD8+ lym-
phocytes. CRC, like most other malignancies, is associated 
with unfavorable shift in immune responses toward Th2 and 
diminished total count of Th1 CD4+ cells, accompanied by 
reduced production of their prototypical cytokines IFNγ and 
IL-12 (reviewed in [50]). Here, we examined the associations 
between IL-7 and other cytokines and growth factors in CRC. 
IL-7 was tightly and positively correlated with Th1 cytokines 
IFNγ, TNFα and IL-12(p70) and Th2 cytokine IL-10, of 
which TNFα and IL-10 remained significantly correlated fol-
lowing adjustment to other associations. IL-7 dependence on 
TNFα is in agreement with stimulatory effect of TNFα on 
the expression of IL-7 [11]. We also observed IL-7 correla-
tion with MCP-1 that might reflect cytokine effect on mono-
cytes/macrophages. Zhang et al. [25] demonstrated that IL-7 
induced macrophage activation and their homing into the gut, 
by inducing MCP-1 expression by intestinal epithelial cells.
In summary, our study is the first to demonstrate IL-7 
elevation in CRC in association with lymph node involve-
ment and tumor location. Both associations should be con-
sidered when designing IL-7-based immunotherapies. Fur-
ther studies on IL-7 functionality in CRC are necessary.
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